Genomtec S.A. launched a public offering of up to 730,000 J-series shares. The maximum price was set at PLN 11 per share. All funds from the issue of shares (7.5 PLN mln after costs of conducting) will be used in preparation for the industrialization and mass production of the Genomtec ID platform. Including received grants, the amount of Company’s investment budget to be implemented in 2020 – H1 2022 will be PLN 17.7 mln.
Genomtec is an innovative biotechnology company founded in 2016 in Wrocław that works in the area of molecular diagnostics. Genomtec’s mission is to empower professionals, including healthcare professionals, to make faster and better decisions when it comes to human health and life. The company is developing a platform for genetic diagnostics and tests to detect infectious diseases of the respiratory tract, including COVID-19 detection.
Genomtec offers shares in a public offering. The offering service in the public offering process is provided by the INC Brokerage house. Declarations of purchase of shares can be submitted until October 22, 2020.